

**Ad hoc release pursuant to § 15 Wertpapierhandelsgesetz  
(German Securities Trading Act)**

**WILEX AG announces change on the Executive Management Board**

**Munich, Germany, 2 June 2016** – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that Professor Andreas Pahl has been appointed to the company's Executive Management Board to serve as the new Head of Research and Development. Professor Pahl will take over this capacity with immediate effect.

Professor Andreas Pahl has worked successfully as Chief Scientific Officer and member of the executive management of WILEX's subsidiary Heidelberg Pharma GmbH since September 2012, and can look back on 20 years' experience in research and higher education. Prior to his position at Heidelberg Pharma, he spent four years as Head of Late Pharmacology at Nycomed and Takeda Pharmaceuticals.

+++ End of the ad-hoc release +++

**About WILEX**

WILEX AG is a biopharmaceutical company which discontinued all clinical development activities at its Munich site and now exercises a holding function as the Group parent. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative ADC platform technology for Antibody-Targeted Amanitin Conjugates (ATAC technology) and provides preclinical drug research and development services. WILEX has the diagnostic and therapeutic drug candidates REDECTANE<sup>®</sup> and RENCAREX<sup>®</sup>, which are available for out-licensing and further development in Phase III for external partners. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at <http://www.wilex.com/>.

**Contact**

**WILEX AG**

Sylvia Wimmer  
Corporate Communications  
Tel.: +49 (0)89-41 31 38-29  
Email: investors[at]wilex.com  
Grillparzerstr. 18, 81675 Munich

**IR/PR-support**

**MC Services AG**

Katja Arnold (CIRO)  
Executive Director & Partner  
Tel.: +49 (0)89-210 228-40  
Mobile: +49 (0)160 9360 3022  
Email: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.